Genoks, a leading genomics healthcare company based in Turkey, has partnered with Velsera, a global healthcare technology firm specializing in a universal software platform connecting clinical care with discovery. Together, they aim to advance cancer diagnostics and treatment not only in Turkey but also in neighboring regions.
The collaboration integrates Genoks’ expertise in genomics with Velsera’s innovative Clinical Genomics Workspace (CGW), a state-of-the-art platform for analyzing data from solid tissue, liquid tumor, and hematological cancer samples. By leveraging CGW’s advanced capabilities in genomic analysis and data interpretation, Genoks enhances its cancer diagnostic services, enabling accurate detection and characterization of various cancer types.
“We are excited to partner with Velsera in our joint mission to revolutionize cancer diagnostics and treatment in Turkey and beyond,” stated Dr. Yunus Alp, MD Clinical Geneticist at Genoks. “Together, we are poised to make a significant impact in combating cancer, empowering clinicians with precise insights to guide treatment decisions and improve patient outcomes.”
CGW, tailored for oncology specialists and clinical laboratories, facilitates Next-Generation Sequencing (NGS) testing programs by providing advanced algorithms and tools. This empowers molecular diagnostics experts globally, from physician-owned laboratories to large hospitals and reference labs, to excel in their practice.
Through this partnership, Genoks aims to strengthen its leadership in oncology diagnostics in Turkey, offering advanced testing solutions for personalized cancer care. The collaboration underscores the role of strategic alliances in advancing cancer research and elevating patient care standards.
About Genoks:
Established in 2008, Genoks is a pioneer in the international genomics market, delivering DNA and RNA sequencing services, as well as solid/liquid cancer screening. With a team of experts and cutting-edge equipment, Genoks has served over 7,000 users across 15+ countries, conducting more than 180,000 NGS analyses. Actively engaged in R&D projects, Genoks continues to innovate and expand its footprint in personalized healthcare. For more information, visit onkogenoks.com and global.genoks.com.tr
About Velsera:
Velsera, formed in 2023 through the merger of Seven Bridges, PierianDx, and UgenTec, operates globally in the US, Europe, and Asia. Dedicated to precision medicine, Velsera provides a comprehensive platform for discovery, evidence generation, and clinical delivery. By empowering clinical diagnostics and life sciences experts, Velsera facilitates informed therapeutic decisions, ensuring the right therapy reaches the right patients at the right time.
